GLP-3: There Is No Such Drug — You Mean GLP-1

This page lives in the PlexusDx Education Hub, where we unpack GLP-1 biology, weight-management options, and the genetic factors sitting beneath each choice. Open the Peptides & GLP-1 library.

If you searched for "GLP-3," there is a good chance a "1" was meant. No drug or hormone class named GLP-3 is in clinical use; the term people are almost always reaching for is the GLP-1 receptor agonists. This short disambiguation clears up the name, explains what the real class is, and points you toward accurate next steps.

Is there such a thing as "GLP-3"?

Not in current medicine. There is no FDA-approved medication class called GLP-3, and no hormone by that name drives the weight and glucose effects people read about. The confusion is understandable given how fast this category has grown, but the correct reference point is glucagon-like peptide-1 — GLP-1 — and the receptor agonists built around it.

What GLP-1 receptor agonists actually are

A GLP-1 receptor agonist engages the glucagon-like peptide-1 receptor; some compounds also engage the GIP receptor, and investigational agents add glucagon receptor agonism. Functionally, these drugs slow gastric emptying, blunt post-meal glucose spikes, and strengthen satiety signaling. They are real, prescription medications with FDA-approved indications — not a mysterious "GLP-3."

The approved GLP-1 medications

The class holds FDA approvals dating to exenatide in 2005 for type 2 diabetes, expanding into chronic weight management with liraglutide (Saxenda) in 2014 and later compounds. Approved products span type 2 diabetes and chronic weight management indications, with the specific label governing each. Most are subcutaneous injections; Rybelsus is the only FDA-approved oral option as of April 2026.

Injection and oral formats

Format is a common source of the underlying confusion. The majority of approved GLP-1 receptor agonists are given as subcutaneous injections, while oral options remain limited. List prices vary by compound and formulation as of April 2026, and what a person pays depends on coverage and the licensed pathway through which a product is obtained.

Where PlexusDx fits

The PlexusDx Weight Management Protocols collection provides semaglutide and tirzepatide through clinician-supervised, 503A-compounded protocols. That is a specific, real offering — a useful contrast to a search term that does not correspond to any actual drug. The value of the disambiguation is practical: once the name is corrected, the entire body of accurate GLP-1 information becomes accessible, from mechanism to labeling to the pharmacy pathways that actually exist. Before any protocol decision, PlexusDx frames the choice around the biology underneath it.

Where your genetics enter the conversation

Whatever you call it, the underlying pathway is genetic before it is pharmacological. The receptor these drugs bind, GLP1R, varies from person to person in ways that influence receptor density and how efficiently the incretin signal travels downstream. Nearby, FTO shapes appetite regulation and where the body sets its adiposity baseline, MC4R governs satiety signaling inside the hypothalamus and total energy intake, and TCF7L2 is tied to insulin secretion and incretin response.

None of these variants forecast how you will respond to a particular medication, and the analysis is not pharmacogenomic. What they do is describe the metabolic terrain a clinician is working within. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across FTO, GLP1R, MC4R, and TCF7L2 — pathway-level context you bring to a provider conversation, never a prediction of drug response or dose. It is the test before you invest idea applied to metabolic care.

Explore the Weight Management Protocols collection or start with the biology through the Precision Peptide Genetic Test. For accurate class background, see GLP-1 Drugs and GLP-1 Hormone.

The bottom line: chasing “GLP-3” leads nowhere, because the real subject is GLP-1. Redirecting the search to the actual class — its approved products, its formats, and the genetics underneath — replaces a phantom term with information you can genuinely use in a conversation about metabolic care.

Frequently Asked Questions

Is "GLP-3" a real medication?

No. There is no drug or hormone class called GLP-3 in clinical use. The term is almost always a misremembering of GLP-1, the incretin hormone whose receptor agonists are used for type 2 diabetes and chronic weight management. If you saw "GLP-3," GLP-1 is what was meant.

What should I search for instead?

Search for GLP-1, GLP-1 receptor agonists, or the specific product names such as semaglutide and tirzepatide. These are the real, FDA-approved references. The PlexusDx Education Hub keeps explainer content on the GLP-1 class and the genetic pathways that sit beneath every protocol decision.

Are GLP-1 receptor agonists prescription drugs?

Yes. They are real, FDA-approved medications available by prescription, most given as subcutaneous injections, with Rybelsus the only approved oral option as of April 2026. PlexusDx offers semaglutide and tirzepatide through clinician-supervised, 503A-compounded protocols within its Weight Management Protocols collection.

Does genetics factor into GLP-1 decisions?

It can, as upstream context. The Precision Peptide Genetic Test never predicts response to any medication, but it analyzes pathway-level variants in FTO, GLP1R, and MC4R that shape baseline GLP-1 biology — information you bring to a provider conversation rather than a treatment recommendation.

Keep exploring the PlexusDx Education Hub for more GLP-1 and metabolic-health explainers. Return to the Education Hub.